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Abstract
Background
The objectives of this study were to identify risk factors for severe coronavirus disease 2019
(COVID-19) and to lay the basis for risk stratification based on demographic data and health
records.
Methods and findings
The design was a matched case-control study. Severe COVID-19 was defined as either a
positive nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in the national database followed by entry to a critical care unit or death within 28 days or a
death certificate with COVID-19 as underlying cause. Up to 10 controls per case matched for
sex, age, and primary care practice were selected from the national population register. For
this analysis—based on ascertainment of positive test results up to 6 June 2020, entry to crit-
ical care up to 14 June 2020, and deaths registered up to 14 June 2020—there were 36,948
controls and 4,272 cases, of which 1,894 (44%) were care home residents. All diagnostic
codes from the past 5 years of hospitalisation records and all drug codes from prescriptions
dispensed during the past 240 days were extracted. Rate ratios for severe COVID-19 were
estimated by conditional logistic regression. In a logistic regression using the age-sex distri-
bution of the national population, the odds ratios for severe disease were 2.87 for a 10-year
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increase in age and 1.63 for male sex. In the case-control analysis, the strongest risk factor
was residence in a care home, with rate ratio 21.4 (95% CI 19.1–23.9, p = 8 × 10−644). Uni-
variate rate ratios for conditions listed by public health agencies as conferring high risk were
2.75 (95% CI 1.96–3.88, p = 6 × 10−9) for type 1 diabetes, 1.60 (95% CI 1.48–1.74, p = 8 ×
10−30) for type 2 diabetes, 1.49 (95% CI 1.37–1.61, p = 3 × 10−21) for ischemic heart disease,
2.23 (95% CI 2.08–2.39, p = 4 × 10−109) for other heart disease, 1.96 (95% CI 1.83–2.10, p =
2 × 10−78) for chronic lower respiratory tract disease, 4.06 (95% CI 3.15–5.23, p = 3 × 10−27)
for chronic kidney disease, 5.4 (95% CI 4.9–5.8, p = 1 × 10−354) for neurological disease,
3.61 (95% CI 2.60–5.00, p = 2 × 10−14) for chronic liver disease, and 2.66 (95% CI 1.86–
3.79, p = 7 × 10−8) for immune deficiency or suppression. Seventy-eight percent of cases
and 52% of controls had at least one listed condition (51% of cases and 11% of controls
under age 40). Severe disease was associated with encashment of at least one prescription
in the past 9 months and with at least one hospital admission in the past 5 years (rate ratios
3.10 [95% CI 2.59–3.71] and 2.75 [95% CI 2.53–2.99], respectively) even after adjusting for
the listed conditions. In those without listed conditions, significant associations with severe
disease were seen across many hospital diagnoses and drug categories. Age and sex pro-
vided 2.58 bits of information for discrimination. A model based on demographic variables,
listed conditions, hospital diagnoses, and prescriptions provided an additional 1.07 bits (C-
statistic 0.804). A limitation of this study is that records from primary care were not available.
Conclusions
We have shown that, along with older age and male sex, severe COVID-19 is strongly asso-
ciated with past medical history across all age groups. Many comorbidities beyond the risk
conditions designated by public health agencies contribute to this. A risk classifier that uses
all the information available in health records, rather than only a limited set of conditions, will
more accurately discriminate between low-risk and high-risk individuals who may require
shielding until the epidemic is over.
Author summary
Why was this study done?
• Most people infected with severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) do not become seriously ill: risk of severe or fatal disease is associated with older
age, male sex, and conditions designated by public health agencies, including asthma,
diabetes, and heart disease.
• Studies reported so far have focused on these “listed conditions” but have not examined
medical records systematically to identify possible risk factors for severe coronavirus
disease 2019 (COVID-19).
• The objectives of this study were to identify risk factors for severe COVID-19 and to lay
the basis for risk stratification based on electronic health records.
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What did the researchers do and find?
• Using Scotland’s capability for linking electronic health records, we report the first sys-
tematic study of the relationship of severe or fatal COVID-19 to preexisting health con-
ditions and other risk factors.
• Residents in care homes were 21 times more likely to develop severe disease than people
of the same age and sex not living in care homes.
• The conditions associated with increased risk include not only those already designated
by public health agencies—asthma, diabetes, heart disease, disabling neurological dis-
ease, kidney disease—but other diagnoses that are associated with frailty and poor health
such as strokes and a history of falls.
• In those without any listed conditions, use of prescribed drugs acting on the digestive
system or nervous system is associated with increased risk of severe COVID-19.
What do these findings mean?
• The risk to younger individuals without any recent history of hospital admission or use
of prescription drugs is very low.
• This study lays a basis for calculating a risk score based on electronic health records for
every individual in the population and using it to advise those at high risk of severe dis-
ease to shield themselves when there is a COVID-19 epidemic in their locality.
Background
Case series from many countries have suggested that, in those with severe coronavirus disease
2019 (COVID-19), the prevalence of diabetes and cardiovascular disease is higher than
expected. For example, in a large United Kingdom series, the commonest comorbidities were
cardiac disease, diabetes, chronic pulmonary disease, and asthma [1]. However, there are also
anecdotal reports of apparently healthy young persons succumbing to disease [2].
Quantification of the risk associated with characteristics and comorbidities has been limited
by the lack of comparisons with the background population [3–5]. Two recent studies in the
UK have included population comparators and have reported associations of hospitalization
with COVID-19 or death from COVID-19 with comorbidities including diabetes, asthma, and
heart disease [6,7]. These studies have focused on conditions presumptively listed by public
health agencies as increasing risk for COVID-19 based on case series data.
Here, we examine the frequency of sociodemographic factors and these listed conditions in
all people with severe COVID-19 disease in Scotland compared to matched controls from the
general population. In those without listed conditions, we report a systematic examination of
the hospitalisation record and prescribing history in severe COVID-19 cases compared to con-
trols. The objectives were to identify risk factors for severe COVID-19 and to lay the basis for
risk stratification based on a predictive model.
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Methods
The protocol of the study dated 16 April 2020, together with all code used to prepare this man-
uscript, is available in a public repository (https://github.com/pmckeigue/covid-scotland_
public). We modified the original protocol to align the list of risk conditions to be consistent
with those designated by public health agencies and extended the list of drug classes under
study to include all drugs. The study was registered with the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance (ENCEPP number http://www.encepp.eu/
encepp/viewResource.htm?id=35559EUPAS35558).
Ethics statement
All record linkage studies using National Health Service (NHS) data in Scotland are governed
by the Public Benefit and Privacy Panel for Health and Social Care, which includes patient and
public representatives. Identifiable data were extracted by the Public Health Scotland Commu-
nity Health Index (CHI) database and linkage team and de-identified before provision to the
analysis team.
Case definition and selection of matched controls
All individuals testing positive for nucleic acid for severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2) were ascertained through the Electronic Communication of Surveillance
in Scotland (ECOSS) database, which captures all virology testing in all NHS laboratories
nationally. Linkage to other datasets was carried out using the CHI number, a unique identifier
used in all care systems in Scotland. Admissions to critical care were obtained from the Scot-
tish Intensive Care Society and Audit Group (SICSAG) database that captures admission to all
critical care (intensive care or high-dependency) units and has returned a daily census of
patients in critical care from the beginning of the COVID-19 epidemic. Death registrations
were obtained from linkage to the National Register of Scotland. Severe or fatal COVID-19
was defined by either (1) a positive nucleic acid test followed by entry to critical care or death
within 28 days or (2) a death certificate with COVID-19 as underlying cause. Using this defini-
tion ensures ascertainment of all severe cases even if they die without testing positive or enter-
ing critical care, whatever selection policies may have limited entry to critical care.
For each case, the CHI database was used to select up to 10 controls who were matched for
sex and 1-year age band, were registered with the same primary care practice, and were alive
and resident in Scotland on the same day as the first date that the case tested positive. For fatal
cases who had not tested positive, the incident date was assigned as 14 days before death. To
ensure that cases and controls were representative of the same population at risk, the 0.6% of
cases that were recorded on the CHI database as no longer alive and resident in Scotland on
the day that ECOSS recorded them as testing positive were also excluded. As this is an inci-
dence density sampling design, it is possible and correct for an individual to appear in the
dataset more than once, initially as a control and subsequently as a case.
For this analysis based on ascertainment of positive test results up to 6 June 2020, entry to
critical care up to 14 June 2020, and deaths registered up to 14 June 2020, there were 4,272
cases and 36,948 controls. Among fatal cases, 94% of deaths were registered within 5 days.
Demographic data
Residence in a care home was ascertained from the CHI database. Socioeconomic status was
assigned as the quintile of the Scottish Index of Multiple Deprivation (SIMD), an indicator
based on postal code. For 74% of controls and 85% of cases, self-assigned ethnicity of the
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individual—based on the categories used in Scotland’s Census—had been recorded in the
Scottish Morbidity Record (SMR).
Morbidity and drug prescribing
For all cases and controls, International Statistical Classification of Diseases Tenth Revision
(ICD-10) diagnostic codes were extracted from the last 5 years of hospital discharge records in
the SMR (SMR01), excluding records of discharges less than 25 days before testing positive for
SARS-CoV-2 and using all codes on the discharge. Diagnostic coding under ICD Chapters V
(Mental, Behavioural and Neurodevelopmental) and XV (Pregnancy) is incomplete because
most psychiatric and maternity unit returns are not captured in SMR01. British National For-
mulary (BNF) drug codes for dispensed prescriptions issued in primary care were extracted
from the Scottish Prescribing Information System [8]. A cutoff date of 15 days before the inci-
dent date (date of testing positive for SARS-CoV-2, or 14 days before death for fatal cases with-
out a positive test) was set, and prescriptions dispensed during a 240-day interval before this
cutoff date were included. For this analysis, prescription codes from BNF chapters 14 and
above—comprising dressings, appliances, vaccines, anaesthesia, and other preparations—were
grouped as “Other.”
We began by scoring a specific list of conditions that have been designated as risk condi-
tions for COVID-19 by public health agencies [9]. A separate list of conditions designates
“clinically extremely vulnerable” individuals who were advised to shield themselves completely
since 24 March 2020: this list includes solid organ transplant recipients, people receiving che-
motherapy for cancer, and people with cystic fibrosis or leukaemia. We did not separately tab-
ulate these conditions because we expected these individuals to be underrepresented among
cases if shielding was adequate.
The 8 listed conditions were scored based on diagnostic codes in any hospital discharge
record during the last 5 years, or encashed prescription of a drug for which the only indica-
tions are in that group of diagnostic codes. The R script included as Supporting Information
contains the derivations of these variables from ICD-10 codes and BNF drug codes. Diagnosed
cases of diabetes were identified through linkage to the national diabetes register (SCI-Dia-
betes), with a clinical classification of diabetes type as type 1, type 2, or Other/Unknown.
Statistical methods
To estimate the relationship of cumulative incidence and mortality from COVID-19 to age
and sex, logistic regression models were fitted to the proportions of cases and noncases in the
Scottish population, using the estimated population of Scotland in mid-year 2019, which was
available by 1-year age group up to age 90 years. To allow for possible nonlinearity of the rela-
tionship of the logit of risk to age, we also fitted generalized additive models, implemented in
the R function gam::gam, with default smoothing function.
For the case-control study, all estimates of associations with severe COVID-19 were based
on conditional logistic regression, implemented as Cox regression in the R function survival::
clogit [10]. Among those cases and controls without any of the predefined conditions, we then
further examined associations of ICD-10 and BNF chapter with severe COVID-19. Restriction
of cases and controls, for instance, to exclude those with any listed condition may generate
strata that do not contain at least one case and at least one control, but these strata are ignored
by the conditional logistic regression model as they do not contribute to the conditional likeli-
hood. With incidence density sampling, the odds ratios in conditional logistic regression mod-
els are equivalent to rate ratios. Note that odds ratios in a matched case-control study are
based on the conditional likelihood; the unconditional odds ratios calculable from the
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frequencies of exposure in cases and controls will differ from these and are biased towards the
null [11]. Although matching on primary care practice will match to some extent for associated
variables such as care home residence, socioeconomic disadvantage, and prescribing practice,
the effects of these variables are still estimated correctly by the conditional odds ratios but with
less precision than in an unmatched study of the same size [11].
To construct risk prediction models, we used stepwise regression alternating between for-
ward and backward steps to maximize the AIC, implemented in the R function stats::step. To
evaluate the contribution of the listed conditions to risk prediction, and the incremental con-
tribution of other information in hospitalisation and prescription records after assigning these
conditions, predictive models were constructed from 3 sets of variables: a baseline set consist-
ing only of demographic variables; a set that included indicator variables for each listed condi-
tion; and an extended set that included demographic variables, indicator variables for listed
conditions, and indicator variables for hospital diagnoses in each ICD-10 chapter and pre-
scriptions in each BNF chapter.
The performance of the risk prediction model in classifying cases versus noncases of severe
COVID-19 was examined by 10-fold cross-validation. We calculated the performance calcu-
lated over all test folds using the C-statistic but also using the “expected information for dis-
crimination” Λ expressed in bits [12]. The use of bits (logarithms to base 2) to quantify
information is standard in information theory: one bit can be defined as the quantity of infor-
mation that halves the hypothesis space. Although readers may be unfamiliar with the expected
information for discrimination Λ, it has several properties that make it more useful than the
C-statistic for quantifying increments in the performance of a risk prediction model [12]. A
key advantage of using Λ is that contributions of independent predictors can be added. There-
fore, in this study we can add the predictive information from a logistic model of age and sex
in the general population to the predictive information provided by other risk factors from the
case-control study matched for age and sex.
Results
Incidence and mortality from severe COVID-19 in the Scottish population
Fig 1 shows the relationships of incidence and mortality rates to age for each sex separately.
The relationship of mortality to age is almost exactly linear on a logit scale, and the lines for
male and female mortality are almost parallel. In models that included age and sex as covari-
ates, the odds ratio associated with a 10-year increase in age was 2.87 for all severe disease and
3.7 for fatal disease. The odds ratio associated with male sex was 1.63 for all severe disease and
1.58 for fatal disease. For severe cases as defined in this study, the sex differential is narrow up
to about age 50 but widens between ages 50 and 70 years. Therefore, at younger ages, the ratio
of critical care admissions to total fatalities is higher in women than in men, but at later ages,
the ratio of critical admissions to total fatalities is higher in men.
Risk factors
Sociodemographic factors. Table 1 shows univariate associations of demographic factors
with severe disease. Residence in a care home was by far the strongest risk factor for severe dis-
ease. Higher risk of severe disease was also associated with socioeconomic deprivation. In the
85% of cases and 74% of controls for whom ethnicity of the individual had been recorded in
the SMR, there were few nonwhite individuals, and the confidence limits for the rate ratios by
ethnic group were wide.
Factors derived from hospitalisation and prescribing records. Prevalence of the listed
conditions in cases and controls by age band is shown in Table 2. Twenty-nine (51%) of the
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Fig 1. Incidence of severe and fatal COVID-19 in Scotland by age and sex: Generalized additive models fitted to
severe and fatal cases for males and females separately. COVID-19, coronavirus disease 2019.
https://doi.org/10.1371/journal.pmed.1003374.g001
Table 1. Univariate associations of severe disease with demographic factors.
Controls Cases Rate ratio (95% CI) p -Value
Number of individuals (entire sample) 36,948 4,272
Most deprived SIMD quintile 8,559 (23%) 1,121 (26%)
7,956 (22%) 935 (22%) 0.86 (0.78–0.95) 0.003
6,730 (18%) 826 (19%) 0.88 (0.79–0.98) 0.02
6,558 (18%) 773 (18%) 0.81 (0.72–0.90) 2 × 10−4
Least deprived SIMD quintile 7,119 (19%) 614 (14%) 0.54 (0.48–0.62) 4 × 10−21
Care home 2,935 (8%) 1,894 (44%) 21.4 (19.1–23.9) 8 × 10−644
Number of individuals (with SMR record of ethnicity) 27,230 3,648
White 26,908 (99%) 3,596 (99%)
South Asian 145 (1%) 27 (1%) 1.26 (0.81–1.97) 0.3
Black 35 (0%) 5 (0%) 1.16 (0.44–3.04) 0.8
Other 142 (1%) 20 (1%) 1.01 (0.63–1.65) 1
Abbreviations: SIMD, Scottish Index of Multiple Deprivation; SMR, Scottish Morbidity Record
https://doi.org/10.1371/journal.pmed.1003374.t001
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cases aged under 40 years had at least one listed condition, compared with only 64 (11%) of
the controls. In those aged 75+ years, 2,346 (84%) of the cases and 14,299 (61%) of the controls
had at least one listed condition. Among those aged under 40 years, 48 (84%) of the cases and
344 (60%) of the controls had either a hospital admission in the last 5 years or a dispensed pre-
scription in the last 240 days. Differences in prescription rates between cases and controls nar-
rowed with increasing age.
Across all age groups, 3,327 (78%) of severe cases and 19,155 (52%) of controls had at least
one of the listed conditions. As shown in Table 3, all the listed conditions were more frequent
in cases than controls except for immune conditions in the 75+ age group. The rate ratio
Table 2. Frequencies of risk factors in cases and controls, by age group.
0–39 years 40–59 years 60–74 years 75+ years
Controls
(570)
Cases
(57)
Controls
(4,168)
Cases
(418)
Controls
(8,734)
Cases
(881)
Controls
(23,476)
Cases
(2,916)
Care home 0 (0%) 1 (2%) 4 (0%) 19 (5%) 90 (1%) 176 (20%) 2,841 (12%) 1,698 (58%)
Any prescription 311 (55%) 47 (82%) 2,916 (70%) 371 (89%) 7,591 (87%) 839 (95%) 22,665 (97%) 2,872 (98%)
Any admission 143 (25%) 26 (46%) 1,474 (35%) 249 (60%) 4,394 (50%) 674 (77%) 16,527 (70%) 2,508 (86%)
Any listed condition 64 (11%) 29 (51%) 1,028 (25%) 225 (54%) 3,764 (43%) 637 (72%) 14,299 (61%) 2,436 (84%)
Diagnosis or prescription 344 (60%) 48 (84%) 3,115 (75%) 386 (92%) 7,815 (89%) 859 (98%) 22,894 (98%) 2,901 (99%)
Type 1 diabetes 0 (0%) 2 (4%) 46 (1%) 12 (3%) 42 (0%) 8 (1%) 70 (0%) 21 (1%)
Type 2 diabetes 3 (1%) 2 (4%) 250 (6%) 75 (18%) 1,319 (15%) 219 (25%) 3,970 (17%) 613 (21%)
Other/unknown type 2 (0%) 4 (7%) 24 (1%) 14 (3%) 73 (1%) 8 (1%) 184 (1%) 22 (1%)
Ischaemic heart disease 2 (0%) 0 (0%) 126 (3%) 34 (8%) 955 (11%) 170 (19%) 4,392 (19%) 702 (24%)
Other heart disease 6 (1%) 7 (12%) 176 (4%) 66 (16%) 1,236 (14%) 265 (30%) 7,192 (31%) 1,411 (48%)
Asthma or chronic airway disease 49 (9%) 22 (39%) 567 (14%) 114 (27%) 1,686 (19%) 328 (37%) 5,306 (23%) 970 (33%)
Chronic kidney disease or transplant
recipient
1 (0%) 0 (0%) 8 (0%) 16 (4%) 30 (0%) 24 (3%) 163 (1%) 57 (2%)
Neurological (except epilepsy) or
dementia
3 (1%) 7 (12%) 61 (1%) 43 (10%) 321 (4%) 177 (20%) 2,897 (12%) 1,154 (40%)
Liver disease 1 (0%) 0 (0%) 20 (0%) 10 (2%) 53 (1%) 21 (2%) 59 (0%) 20 (1%)
Immune deficiency or suppression 2 (0%) 1 (2%) 18 (0%) 13 (3%) 47 (1%) 15 (2%) 76 (0%) 11 (0%)
https://doi.org/10.1371/journal.pmed.1003374.t002
Table 3. Associations of severe disease with listed conditions over all age groups.
Univariate Multivariable
Controls (36,948) Cases (4,272) Rate ratio (95% CI) p -Value Rate ratio (95% CI) p -Value
Care home 2,935 (8%) 1,894 (44%) 21.4 (19.1–23.9) 8 × 10−644 14.7 (13.1–16.6) 1 × 10−431
Any prescription 33,483 (91%) 4,129 (97%) 3.10 (2.59–3.71) 8 × 10−35 1.83 (1.51–2.22) 6 × 10−10
Any admission 22,538 (61%) 3,457 (81%) 2.75 (2.53–2.99) 2 × 10−124 1.56 (1.41–1.72) 1 × 10−18
Type 1 diabetes 158 (0%) 43 (1%) 2.75 (1.96–3.88) 6 × 10−9 1.56 (1.05–2.32) 0.03
Type 2 diabetes 5,542 (15%) 909 (21%) 1.60 (1.48–1.74) 8 × 10−30 1.42 (1.29–1.56) 3 × 10−13
Other/unknown type 283 (1%) 48 (1%) 1.74 (1.28–2.38) 4 × 10−4 1.58 (1.11–2.27) 0.01
Ischaemic heart disease 5,475 (15%) 906 (21%) 1.49 (1.37–1.61) 3 × 10−21 1.08 (0.98–1.20) 0.1
Other heart disease 8,610 (23%) 1,749 (41%) 2.23 (2.08–2.39) 4 × 10−109 1.33 (1.22–1.46) 2 × 10−10
Asthma or chronic airway disease 7,608 (21%) 1,434 (34%) 1.96 (1.83–2.10) 2 × 10−78 1.54 (1.42–1.68) 7 × 10−25
Chronic kidney disease or transplant recipient 202 (1%) 97 (2%) 4.06 (3.15–5.23) 3 × 10−27 2.88 (2.13–3.89) 7 × 10−12
Neurological (except epilepsy) or dementia 3,282 (9%) 1,381 (32%) 5.4 (4.9–5.8) 1 × 10−354 2.00 (1.81–2.21) 2 × 10−42
Liver disease 133 (0%) 51 (1%) 3.61 (2.60–5.00) 2 × 10−14 1.93 (1.32–2.81) 6 × 10−4
Immune deficiency or suppression 143 (0%) 40 (1%) 2.66 (1.86–3.79) 7 × 10−8 1.67 (1.10–2.52) 0.01
https://doi.org/10.1371/journal.pmed.1003374.t003
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associated with type 1 diabetes was higher than that for type 2 diabetes. The rate ratio was 1.49
(95% CI 1.37–1.61) for ischemic heart disease compared to 2.23 (95% CI 2.08–2.39) for the
broad category “other heart disease.” In multivariable analysis, ischemic heart disease was not
independently associated with severity, whereas other heart disease remained strongly associ-
ated. In those without a listed condition, 873 (92%) of the cases and 15,052 (85%) of the con-
trols had either a recent admission or a prescription. In those aged under 60 years without a
listed condition, 184 (83%) of the cases and 2,376 (65%) of the controls had either a recent
admission or a prescription.
S1–S3 Tables examine these associations by age group, with the 0–39 and 40–59 year age
bands combined. All listed conditions were associated with severe disease in each age band. In
those aged under 60 years, the rate ratio was 3.70 (95% CI 2.01–6.79) for type 1 diabetes and
3.70 (95% CI 2.80–4.90) for type 2 diabetes. The multivariable analyses shown in Table 3 and
S1–S3 Tables show that, overall and in each age group, any admission to hospital in the past 5
years was strongly and independently associated with severe disease even after adjusting for
care home residence and listed conditions. Dispensing of any prescription in the past year was
associated with severe disease in multivariable analyses in the 2 younger age bands. Table 4
shows that, in each age group, the proportion of fatal cases who had not had either a hospital
admission in the last 5 years or a dispensed prescription in the last year was very low.
Comparison of fatal and nonfatal cases
S4 Table shows a breakdown of severe cases by test-positive status of the patient, entry to criti-
cal care, and fatal versus nonfatal outcome. Severe cases who entered critical care were much
younger than severe cases never entering critical care. Most severe cases who were resident in
a care home never entered critical care. Among fatal cases who did not enter critical care, the
distribution of age and other risk factors was similar in those with and without a positive test
result, except that the proportion of care home residents was higher among those without a
positive test result. Among those entering critical care, median age, proportion of males, and
prevalence or prior comorbidities were higher in fatal than in nonfatal cases.
Systematic analysis of diagnoses associated with severe disease
The association of severe COVID-19 with prior hospital admission was examined further by
testing for association of hospitalisations at each ICD-10 chapter level with severe COVID-19,
among those without any of the listed conditions. These results are shown in S5 Table. In uni-
variate analyses, almost all ICD-10 chapters, with the exception of Chapters VII (eye), VIII
Table 4. Proportions of fatal cases and matched controls without and with a dispensed prescription or hospital
diagnosis, by age group.
Controls Fatal cases
Age <60 years
No prescription or diagnosis 1,305 (26%) 15 (7%)
Prescription or diagnosis 3,696 (74%) 197 (93%)
Age 60–74 years
No prescription or diagnosis 929 (10%) 12 (2%)
Prescription or diagnosis 7,994 (90%) 680 (98%)
Age 75+
No prescription or diagnosis 583 (2%) 14 (0%)
Prescription or diagnosis 22,924 (98%) 2,871 (100%)
https://doi.org/10.1371/journal.pmed.1003374.t004
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(ear), and XV (pregnancy), were associated with increased risk of severe disease. In a multivar-
iable analysis, the strongest associations were with diagnoses in ICD chapters IV (mental dis-
orders) and X (respiratory). S7 Table extracts univariate associations with ICD-10 subchapters
in those without any listed conditions. This table is filtered to show only subchapters for which
there are at least 50 cases and controls and the univariate p-value is<0.001. This shows that
many subchapter diagnoses are associated with markedly higher risk of severe COVID-19.
Associations of prescribed drugs with severe disease
As shown in Table 3 and S1–S3 Tables, encashment of at least one prescription in the last year
was associated with severe disease. The univariate rate ratio associated with this variable varies
from 3.74 (95% CI 2.79–5.01) in those aged under 60 years to 2.30 (95% CI 1.69–3.14) in those
aged 75 years and over. In a multivariable analysis adjusting for care home residence, any hos-
pital admission, and listed conditions, these rate ratios were reduced to 2.12 (95% CI 1.55–
2.90) and 1.13 (95% CI 0.80–1.60), respectively.
To investigate this further, we partitioned the “Any prescription” variable into indicator
variables for each chapter of the BNF, in which drugs are grouped by broad indication, and
restricted the analysis to those without one of the listed conditions. S6 Table shows these asso-
ciations. In univariate analyses, prescriptions in almost all BNF chapters were associated with
severe disease. In a multivariable analysis of all chapters, the strongest independent associa-
tions with severe disease were with prescriptions in chapters 1 (gastrointestinal), 4 (central ner-
vous system), 5 (infections), 9 (nutrition and blood), and 14+ (other, mostly dressings and
appliances).
Construction of a multivariable risk prediction model
The variables retained from the extended variable set (demographic variables, listed condi-
tions, hospital diagnoses in each ICD-10 chapter, prescriptions in each BNF chapter) are
shown in S8 Table. Coefficients for specific conditions here should not be interpreted as effect
estimates, as global variables for any hospital diagnosis and any listed condition have been
included in the model. The predictive performance of the model chosen by stepwise regression
was estimated by 10-fold cross-validation. Observed and predicted case-control status was
compared within each stratum over all test folds. Table 5 shows that, in comparison with using
only demographic variables and listed conditions, using the extended variable set increased
the C-statistic from 0.776 to 0.804 and the expected information for discrimination Λ from
0.88 bits to 1.07 bits.
Fig 2 shows the distributions in cases and controls of the weight of evidence favouring case
over control status from the model based on the extended variable set with a footnote explain-
ing how Λ is derived. This shows, as expected for a multifactorial classifier, that the distribu-
tion in controls is approximately Gaussian: there is no clear divide between high-risk and low-
risk individuals of the same age and sex. The distribution in cases is bimodal; the second mode
Table 5. Prediction of severe COVID-19: Cross-validation of models chosen by stepwise regression.
Cases/controls Crude C-statistic Adjusted C-statistic CrudeΛ (bits) AdjustedΛ (bits) Test log-likelihood (nats)
Demographic only 2,724/19,509 0.737 0.716 0.65 0.58 0.0
Demographic + listed conditions 2,724/19,509 0.794 0.776 0.95 0.88 389.8
Extended variable set 2,724/19,509 0.812 0.804 1.11 1.07 596.7
Abbreviation: COVID-19, coronavirus disease 2019
https://doi.org/10.1371/journal.pmed.1003374.t005
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of this distribution represents care home residents. Fig 3 shows the receiver operating charac-
teristic curve with a footnote explaining its derivation from the distributions of the weights of
evidence.
The information for discrimination obtained from the matched case-control study which
conditions on age and sex (1.07 bits) can be added to the information for discrimination
obtained from the logistic regression on age and sex in the population (2.58 bits). This gives
3.65 bits as the total information for discrimination of a risk classifier that would be obtained
in the population.
Discussion
Sociodemographic factors
This analysis confirms that risk for severe COVID-19 is associated with increasing age, male
sex, and socioeconomic deprivation. The slope of the relationship of severe disease (on the
scale of log odds) to age is less steep than the slope of the relationship of fatal disease to age.
Residence in a care home was associated with a 21-fold increased rate of severe COVID-19 in
this age-matched analysis, reduced to 15-fold by adjustment for listed conditions. This excess
Fig 2. Cross-validation of model chosen by stepwise regression using extended variable set: Class-conditional
distributions of weight of evidence. For each individual, the risk prediction model outputs the posterior probability of
case status, which can also be expressed as the posterior odds. Dividing the posterior odds by the prior odds gives the
likelihood ratio favouring case over noncase status for an individual. The weight of evidence W is the logarithm of this
ratio. The distributions of W in cases and controls in the test data are plotted in Fig 2. For a classifier, the further apart
these curves are, the better the predictive performance. The expected information for discrimination Λ is the average
of the mean of the distribution of W in cases and −1 times the mean of the distribution of W in controls. The
distributions have been adjusted by taking a weighted average to make them mathematically consistent [12].
https://doi.org/10.1371/journal.pmed.1003374.g002
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risk is likely to reflect both the spread of the epidemic in care homes and residual confounding
by frailty.
As the proportion of the Scottish population that is of nonwhite ethnicity is low and the
assignment of ethnicity in this dataset is incomplete, the confidence intervals for the rate ratios
associated with South Asian and black ethnicity are wide. Studies from England [6,7,13] have
reported elevations in risk of hospitalised and fatal COVID-19 in nonwhite ethnic groups; in
the OpenSAFELY study, the risk ratios for fatal COVID-19 associated with black and Asian
ethnicity were 1.7 and 1.6, respectively. The confidence intervals in this study are compatible
with the effect sizes estimated in England.
Comorbidities
We have confirmed that the moderate risk conditions designated by the NHS and other agen-
cies [9] are associated with increased risk of severe COVID-19. The rate ratios of 2.8 for type 1
diabetes and 1.6 for type 2 diabetes are broadly similar to those reported in the UK Biobank
[13] and OpenSAFELY [7] studies. We confirm the higher risk with asthma and chronic lung
disease and liver disease reported in these and earlier studies. The rate ratios associated with
Fig 3. Cross-validation of model chosen by stepwise regression using extended variable set: ROC curve. The ROC
curve is computed by calculating at each value of the risk score the sensitivity and specificity of a classifier that uses this
value as the threshold for classifying cases and noncases. Using the adjusted distributions from Fig 2 gives a curve that
is concave downwards. The C-statistic is the area under this curve, computed as the probability of correctly classifying
a case/noncase pair using the risk score, evaluated over all possible such pairs in the dataset. ROC, receiver operator
characteristic.
https://doi.org/10.1371/journal.pmed.1003374.g003
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these risk conditions vary with age: for example, the rate ratio associated with diabetes is
higher at younger ages. An unexpected finding was that the risk associated with other forms
of heart disease is higher than that associated with ischaemic heart disease. This category
includes conditions such as atrial fibrillation, cardiomyopathies, and heart failure. One of the
highest rate ratios is that associated with chronic kidney disease. Prevention of nosocomial
transmission in dialysis units may help to reduce this risk. Over all age groups, 78% of severe
cases had at least one of these listed conditions. In this dataset, it is not possible to adequately
examine the risk associated with neoplasms as we cannot separately identify those who were
advised to shield themselves because they had active neoplasms of lymphoid or hematopoi-
etic tissue or were receiving treatments that affect the immune system. We plan to explore
this in a separate study based on linkage to records of shielding advice. In patients without
any listed conditions, further systematic evaluation of past hospitalisation history did not
reveal a sparse set of underlying conditions; instead, many diagnoses were associated with
severe COVID-19.
Public health agencies [14] and media reports of apparently healthy young people succumb-
ing to severe COVID-19 [2] have disseminated the message that all are at risk of severe
COVID-19 whatever their age or health status. However, we found that half of cases who were
under 40 years old had at least one of the listed conditions, and among those who did not have
one of these conditions, the proportions who had at least one prior hospitalisation or dis-
pensed prescription were higher in cases than in controls. In all age groups, very few of the
fatal cases had not had either a hospital admission in the past 5 years or a dispensed prescrip-
tion in the past year.
A striking finding of this study was the association of severe COVID-19 with dispensing of
at least one prescription in the 240-day interval preceding the cutoff of 15 days before diagno-
sis, only partly explained by higher rates of prescribing among those with listed conditions.
Partitioning of this association between BNF chapters, which represent broad indication-
based drug classes, showed that prescribing of drugs for the gastrointestinal and central ner-
vous systems, together with nutritional supplements, contributed to this association. Although
it is likely that most associations of severe COVID-19 with drug prescribing are attributable to
the indications for which these drugs were prescribed—or to more diffuse frailty, especially in
older persons—causal effects of drugs or direct effects of polypharmacy on susceptibility can-
not be ruled out. These associations are explored in a separate paper.
Relevance to policy
As lockdown restrictions are eased, there is general agreement that vulnerable individuals will
require shielding, even if the restart of the epidemic can be slowed or suppressed by mass test-
ing, contact tracing, and isolation of those who test positive. The “stratify and shield” policy
option [15]—in which high-risk individuals are shielded for a defined period while the epi-
demic is allowed to run relatively quickly in low-risk individuals until herd immunity is
attained—depends critically on informative risk discrimination. So too does the similarly
named “segment and shield” option [16], which has the opposite objective of keeping trans-
missions low. Although in this preliminary study we have not used the full repertoire of
machine learning methods available for constructing predictive models, we have shown that a
model based on health records provides 1.07 bits of information for discrimination condi-
tional on age and sex. Adding this to the 2.58 bits provided by age and sex gives a total infor-
mation for discrimination of 3.7 bits. We have shown elsewhere that this level of predictive
performance would allow at least 80% of those at risk of severe or fatal disease to be allocated
to a shielded group that composes no more than 15% of the population [15].
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As awareness grows of how risk varies between individuals, individuals will seek informa-
tion about their own level of risk. A key implication of our results is that risk of severe or fatal
disease is multifactorial. The rate ratio of 2.9 associated with a 10-year increase in age is stron-
ger than the rate ratios associated with common diseases such as asthma or type 2 diabetes that
are listed as conditions associated with high risk. A corollary of this is that a crude classifica-
tion based on assigning all persons with a listed condition to a group for whom shielding is
recommended will have poor specificity, as one-quarter of those aged 60–74 years in the popu-
lation have at least one of the listed conditions that we examined. It will also exclude many
people at high risk because they have multiple risk factors each of small effect. A more mean-
ingful way to score risk for an individual would be to use all available information to calculate
a “COVID age” as the age at which the average risk for someone of the same sex in the popula-
tion equates to the risk for the individual under study. Thus, the rate ratio of 2.8 associated
with type 1 diabetes equates to an increase of 9.8 years in COVID age. In Scotland, it is techni-
cally possible to use existing electronic health records to calculate a risk score for every individ-
ual in the population, though more work would be required to develop this as a basis for
official advice and individual decisions.
Methodological strengths and weaknesses
Most reports of disease associations with COVID-19 have been case series. There have been
few reports based on evaluating these associations in the population through cohort or case-
control studies. With this matched case-control design using incidence density sampling, we
have been able to estimate rate ratios conditional on age and sex. The OpenSAFELY study has
explored associations of a similar set of risk conditions with in-hospital COVID-19 deaths [7]
but has not yet reported a systematic evaluation of the rest of the medical record including pre-
scription records. Although we have records of encashment of prescriptions, we do not at pres-
ent have access to other primary care data, which would contain additional information on
morbidity and measurements such as body mass index. A strength of our study, however, is
that hospital discharge diagnoses are coded to ICD-10 by trained coders, in contrast to the
coding systems used in primary care databases that do not map to recognized disease classifi-
cations. Associations with ethnicity and other sociodemographic factors are not necessarily
generalizable from Scotland to other populations.
Conclusion
This study confirms that risk of severe COVID-19 is associated with sociodemographic factors
and with chronic conditions such as diabetes, asthma, circulatory disease, and others. How-
ever, the associations with preexisting disease are not just with a small set of conditions that
contribute to risk but with many conditions as demonstrated by associations with past medical
and prescribing history in relation to multiple physiological systems. As countries attempt to
emerge from lockdown while protecting vulnerable individuals, multivariable classifiers rather
than crude rule-based approaches will be needed to define those most at risk of developing
severe disease.
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